Purpose, strategy and culture

We are a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. 

We aim to positively impact the health of 2.5 billion people by the end of the decade, as a successful, growing company where people can thrive.

Our strategy

We are a focused biopharma company. We prevent and treat disease with vaccines, specialty and general medicines. We focus on the science of the immune system and advanced technologies, investing in four core therapeutic areas: infectious diseases, HIV, respiratory/immunology, and oncology. Our Ahead Together strategy means intervening early to prevent and change the course of disease, helping to protect people and support healthcare systems. 


Our R&D approach

Partner with GSK

Our portfolio

Shingles Science Image



Our broad vaccines portfolio targets infectious diseases at every stage of life, helping to protect people from meningitis, shingles, RSV, flu, polio and many more. Our portfolio of more than 20 marketed vaccines is one of the industry’s broadest. We deliver over 1.5 million doses of our vaccines every day; and 4 out of 10 infants born each year receive at least one GSK vaccine. Our vaccines portfolio targets infectious diseases at every stage of life, helping to protect people from RSV, meningitis, shingles, flu, polio and many more.

HIV Science Image

Specialty medicines

Specialty medicines

Specialty medicines are prescribed by specialist healthcare practitioners. Our portfolio of specialty medicines prevents and treats diseases, from HIV to respiratory diseases, immune-mediated conditions like lupus, and cancer. Many are first or best-in-class. Our specialty medicines is focused on four therapeutic areas: infectious diseases, HIV, respiratory/immunology and oncology. We’re leaders in infectious diseases and HIV innovation and we’re building our positions in immunology and oncology.

Escherichia Coli (E. Coli) Bacteria Science Image

General medicines

General medicines

General medicines are usually prescribed in primary care or community settings by general healthcare practitioners. General medicines include our inhaled medicines for asthma and COPD, antibiotics and medicines for skin diseases, in a portfolio which includes pre-launch R&D assets, growth and established products. Every day, our general medicines improve health and make life better for millions all over the world and our portfolio of more than 150 primary care products supplied in 112 countries worldwide.

Our therapeutic areas

Influenza Science Image

Infectious diseases

Infectious diseases

There’s a huge need for innovation to tackle chronic infections, seasonal infections, common childhood diseases, rare but devastating conditions (meningitis) and a range of bacterial infections made more challenging by antimicrobial resistance (AMR); as well as diseases which predominately impact lower-income countries like malaria and TB.

Our infectious diseases portfolio is the broadest in the industry and, including HIV, accounts for two thirds of our pipeline.

HIV Science Image



Our goal is to minimise the impact of HIV on people’s lives through treatment, prevention and ultimately cure.

We are a world leader in next-generation HIV treatment and prevention, through ViiV Healthcare, the world’s only specialist HIV pharmaceutical company, which we majority own. We pioneered the first HIV treatments in the 1980s and we are leading the way in changing the landscape for people living with HIV today.

Lupus Science Image

Respiratory/ immunology

Respiratory/ immunology

We’re unlocking the science of the immune system to develop medicines for immune-mediated conditions including lupus, eosinophilic-driven diseases such as severe eosinophilic asthma, COPD and other inflammatory diseases.

Our innovative medicines help millions of people with immune and respiratory conditions.

Immuno Oncology Science Image



Our approach in oncology is to prioritise the development of novel medicines to treat blood and women’s cancers and to explore other potential breakthroughs in immuno-oncology.

We have 11 investigational medicines in our oncology pipeline that have the potential to make a meaningful difference for patients with cancer, and we’re growing our pipeline through targeted business development.

Our long-term priorities

Our culture

Culture at GSK is something we all own. It powers our purpose, drives delivery of our strategy and helps make GSK a place where people can thrive. Our culture of being ambitious for patients, accountable for impact and doing the right thing is the foundation for how, together, we’ll deliver for patients, shareholders and GSK people.

Our Code sets out the commitments GSK and our people make to get ahead together – so we can deliver on our ambition in the right way, bring our culture to life and make GSK an exciting and inspiring place to work.


Meet our Outstanding people


Innovating together

Meet Geeta – finding inspiration by making a difference

18 July 2022

My GSK story

Meet Samuel: helping get medicines to our patients

25 October 2022

Working together

Meet Jess: advocating for patients

02 November 2022

GSKH team member


Our film series brings together our people from teams across the world to discuss the issues that matter across the themes of diversity, equity and inclusion, and explore their different perspectives.